Keros Therapeutics (NASDAQ:KROS) Raised to “Hold” at TD Cowen

Keros Therapeutics (NASDAQ:KROS) was upgraded by investment analysts at TD Cowen to a “hold” rating in a report issued on Friday,Zacks.com reports.

Several other brokerages have also recently weighed in on KROS. Wells Fargo & Company decreased their price objective on shares of Keros Therapeutics from $26.00 to $23.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 11th. Zacks Research upgraded Keros Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Friday, November 7th. Bank of America lifted their price objective on Keros Therapeutics from $18.00 to $19.00 and gave the company a “neutral” rating in a research report on Friday, November 28th. Oppenheimer reaffirmed an “outperform” rating and issued a $27.00 price target (up from $23.00) on shares of Keros Therapeutics in a report on Wednesday, November 12th. Finally, Wedbush raised their price objective on shares of Keros Therapeutics from $15.00 to $16.00 and gave the company a “neutral” rating in a research report on Thursday, November 6th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $21.38.

Keros Therapeutics Price Performance

Shares of KROS stock opened at $20.26 on Friday. The stock’s fifty day simple moving average is $17.36 and its 200 day simple moving average is $15.60. Keros Therapeutics has a one year low of $9.12 and a one year high of $22.55. The firm has a market cap of $617.32 million, a price-to-earnings ratio of 13.16, a P/E/G ratio of 0.25 and a beta of 0.89.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.11) by $0.93. Keros Therapeutics had a return on equity of 9.51% and a net margin of 26.12%.The company had revenue of $14.26 million during the quarter, compared to analysts’ expectations of $4.22 million. During the same period last year, the business earned ($1.41) earnings per share. The business’s revenue was up 3585.6% on a year-over-year basis. On average, research analysts anticipate that Keros Therapeutics will post -4.74 earnings per share for the current year.

Insider Activity

In other news, major shareholder Adar1 Capital Management, Llc sold 5,389,264 shares of the company’s stock in a transaction dated Wednesday, October 15th. The stock was sold at an average price of $17.75, for a total value of $95,659,436.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Pontifax Management 4 G.P. (20 sold 4,787,331 shares of the stock in a transaction that occurred on Wednesday, October 15th. The shares were sold at an average price of $17.75, for a total transaction of $84,975,125.25. The disclosure for this sale is available in the SEC filing. 20.60% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Keros Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. Tower Research Capital LLC TRC raised its stake in Keros Therapeutics by 149.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company’s stock worth $42,000 after buying an additional 1,888 shares during the period. Farther Finance Advisors LLC acquired a new stake in shares of Keros Therapeutics during the third quarter worth about $47,000. CWM LLC raised its position in shares of Keros Therapeutics by 87.5% during the second quarter. CWM LLC now owns 5,000 shares of the company’s stock worth $67,000 after purchasing an additional 2,333 shares during the period. SG Americas Securities LLC bought a new position in shares of Keros Therapeutics during the 3rd quarter valued at about $103,000. Finally, Police & Firemen s Retirement System of New Jersey grew its position in shares of Keros Therapeutics by 29.7% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 8,257 shares of the company’s stock valued at $110,000 after purchasing an additional 1,892 shares during the period. Institutional investors and hedge funds own 71.56% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.